Agoracom Blog

The Roundup – @Novamind_Inc $ $NVMDF $ $MMED $ $ $CMPS $

Posted by AGORACOM-JC at 10:24 AM on Saturday, May 29th, 2021

A weekly summary of Novamind news and media

FEATURES May 28, 2021

Laying the groundwork for the psychedelic revolution

Novamind COO Pierre Bou-Mansour discusses rapid expansion, staying consistent and Novamind’s ultimate goal.

We want to set a new standard of mental healthcare, and be the network that patients prefer—to become a trusted partner for innovative mental healthcare.

View all media

How a psychedelic 12-step program is saving lives

Focused on creating a safe space “to incorporate psychedelic medicine into recovery,” Dimitri M. is a living embodiment of the wounded healer. A former heroin addict whose life was changed by Ibogaine and a 12-step program. Since he’s gone on to form Psychedelics in Recovery and is holding up to 17 meetings a week over zoom. Access to psychedelic medicine in the right situation can be life-changing. Dr. Reid Robison calls psychedelics “therapy accelerators.” Learn more about our innovative approach to psychedelic medicine here. 

MAPS wins appeal and authorization to study MDMA in healthy volunteer therapists

A study that had been on hold for almost two years has been approved. MAPS will hold a phase 1 clinical trial of MDMA-assisted therapy for healthcare workers. Working in conjunction with the FDA, MAPS was able to win the appeal and help “improve the regulatory landscape for all future patients of psychedelic-assisted medicines.” The study “will measure development of self-compassion, professional quality of life, and professional burnout among clinicians delivering the treatment to patients.” This study will address a critical area of need for healthcare workers. 

Follow @novamind_inc on Instagram


For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , , ,

Comments are closed.